ANCA-Associated Vasculitis, Anti-GBM Disease, Complement- and Ig-Mediated Glomerular Disease
By:
Jan Stephan Sanders Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Search for other papers by Jan Stephan Sanders in
Current site
Google Scholar
PubMed Close
and
Coen A. Stegeman Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Search for other papers by Coen A. Stegeman in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 24: Issue 1
Published Online:
Mar 2025
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand
Cover Nephrology Self-Assessment Program
Copyright:
Copyright © 2025 by the American Society of Nephrology 2025
Page Count:
15
Article Category:
Research Article
Print Publication Date:
01 Mar 2025
Published Online:
Mar 2025
  • 1.

    Kronbichler A, Bajema IM, Bruchfeld A, Mastroianni Kirsztajn G, Stone JH: Diagnosis and management of ANCA-associated vasculitis. Lancet 403: 683–698, 2024 10.1016/S0140-6736(23)01736-1 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Floege J, Jayne DRW, Sanders J-SF, Tesar V, Rovin BH: KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int 105: S71–S116, 2024 10.1016/j.kint.2023.10.008 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al.: Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21: 1628–1636, 2010 10.1681/ASN.2010050477 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Brix SR, Noriega M, Tennstedt P, Vettorazzi E, Busch M, Nitschke M, et al.: Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int 94: 1177–1188, 2018 10.1016/j.kint.2018.07.020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Bate S, McGovern D, Costigliolo F, Tan PG, Kratky V, Scott J, et al.: The improved kidney risk score in ANCA-associated vasculitis for clinical practice and trials. J Am Soc Nephrol 35: 335–346, 2024 10.1681/ASN.0000000000000274 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Sandino-Bermudez MJ, Hernandez-Andrade A, Hinojosa-Azaola A, Martin-Nares E, Mejia-Vilet JM: Performance of clinical and histological prognostic scores for kidney survival in ANCA-associated vasculitis [published online ahead of print Jun 14, 2024]. Rheumatology (Oxford) doi:10.1093/rheumatology/keae336 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Floege J, Jayne DRW, Sanders JF, Tesar V, Balk EM, Gordon CE, et al.: Executive summary of the KDIGO 2024 clinical practice guideline for the management of ANCA-associated vasculitis. Kidney Int 105: 447–449, 2024 10.1016/j.kint.2023.10.009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, et al.: EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 83: 30–47, 2024 10.1136/ard-2022-223764 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Wallace ZS, Fu X, Cook C, Ahola C, Williams Z, Doliner B, et al.: Comparative effectiveness of rituximab- versus cyclophosphamide-based remission induction strategies in antineutrophil cytoplasmic antibody-associated vasculitis for the risk of kidney failure and mortality. Arthritis Rheumatol 75: 1599–1607, 2023 10.1002/art.42515 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Ishikawa Y, Tokutsu K, Nakayamada S, Kuchiba A, Fushimi K, Matsuda S, et al.: Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: A propensity score analysis of the real-world nationwide database. Ann Rheum Dis 83: 103–111, 2024 10.1136/ard-2023-224472 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Furuta S, Ikeda K, Nakajima H: Reduced-dose vs high-dose glucocorticoids added to rituximab and remission induction in ANCA-associated vasculitis-reply. JAMA 326: 1536–1537, 2021 10.1001/jama.2021.13879 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, et al.; LoVAS collaborators: Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: Predefined 2-year follow-up study. Ann Rheum Dis 83: 96–102, 2024 10.1136/ard-2023-224343 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Scherbacher PJ, Hellmich B, Feng YS, Loffler C: Prospective study of complications and sequelae of glucocorticoid therapy in ANCA-associated vasculitis. RMD Open 10: e003956, 2024 10.1136/rmdopen-2023-003956 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Jayne DRW, Merkel PA, Schall TJ, Bekker P, Group AS, ADVOCATE Study Group: Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384: 599–609, 2021 10.1056/NEJMoa2023386 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Cortazar FB, Niles JL, Jayne DRW, Merkel PA, Bruchfeld A, Yue H, et al.; ADVOCATE Study Group: Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan. Kidney Int Rep 8: 860–870, 2023 10.1016/j.ekir.2023.01.039 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Patel NJ, Jayne DRW, Merkel PA, Bekker P, Zhang Y, Yue H, et al.: Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: Post-hoc analysis of data from the ADVOCATE trial. Lancet Rheumatol 5: e130–e138, 2023 10.1016/S2665-9913(23)00030-9 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Strand V, Jayne DRW, Horomanski A, Yue H, Bekker P, Merkel PA, et al.; ADVOCATE Study Group: The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: A post-hoc analysis of data from the ADVOCATE trial. Lancet Rheumatol 5: e451–e60, 2023 10.1016/S2665-9913(23)00092-9 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Geetha D, Dua A, Yue H, Springer J, Salvarani C, Jayne D, et al.; ADVOCATE Study Group: Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial. Ann Rheum Dis 83: 223–232, 2024 10.1136/ard-2023-224816 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Smith RM, Jones RB, Specks U, Bond S, Nodale M, Al-Jayyousi R, et al.; RITAZAREM co-investigators: Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: An international randomised controlled trial. Ann Rheum Dis 82: 937–944, 2023 10.1136/ard-2022-223559 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Gabilan C, Belliere J, Moranne O, Pfirmann P, Samson M, Delattre V, et al.: Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: A multicenter real-world study [published online ahead of print Jul 13, 2024]. Rheumatology (Oxford) doi:10.1093/rheumatology/keae359 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Draibe J, Espigol-Frigole G, Cid MC, Prados MC, Guillen E, Villacorta J, et al.: The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain [published online ahead of print Oct 1, 2024]. Rheumatology (Oxford) doi:10.1093/rheumatology/keae534 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Walsh M, Merkel PA, Peh CA, Szpirt WM, Puechal X, Fujimoto S, PEXIVAS Investigators, et al.: Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382: 622–631, 2020 10.1056/NEJMoa1803537 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Walsh M, Collister D, Zeng L et al,: The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ 376: e064604, 2022.

    • PubMed
    • Export Citation
  • 24.

    Junek ML, Merkel PA, Vilayur E, Wald R, Khalidi N, Jayne D, et al.; PEXIVAS Investigators: Risk of relapse of antineutrophil cytoplasmic antibody-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids. Arthritis Rheumatol 76: 1431–1438, 2024 10.1002/art.42843 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Fussner LA, Flores-Suarez LF, Cartin-Ceba R, Specks U, Cox PG, Jayne DRW, et al.; PEXIVAS Investigators: Alveolar hemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis: Results of an international randomized controlled trial (PEXIVAS). Am J Respir Crit Care Med 209: 1141–1151, 2024 10.1164/rccm.202308-1426OC PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Charles P, Terrier B, Perrodeau E, Cohen P, Faguer S, Huart A, et al.; French Vasculitis Study Group: Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77: 1143–1149, 2018 10.1136/annrheumdis-2017-212878 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Khoudour N, Delestre F, Jabot-Hanin F, Jouinot A, Nectoux J, Letouneur F, et al.: Association between plasma rituximab concentration and the risk of major relapse in antineutrophil cytoplasmic antibody-associated vasculitides during rituximab maintenance therapy. Arthritis Rheumatol 75: 2003–2013, 2023 10.1002/art.42556 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Delestre F, Charles P, Karras A, Pagnoux C, Neel A, Cohen P, et al.; French Vasculitis Study Group (FVSG): Rituximab as maintenance therapy for ANCA-associated vasculitides: Pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Ann Rheum Dis 83: 233–241, 2024 10.1136/ard-2023-224623 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Zonozi R, Cortazar FB, Jeyabalan A, Sauvage G, Nithagon P, Huizenga NR, et al.: Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: A randomised trial. Ann Rheum Dis 83: 351–359, 2024 10.1136/ard-2023-224489 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Renson T, Kelly MM, Benediktsson H, Grundhoefer N, Luca N, Miettunen P, et al.: Non-invasive biomarkers of disease activity and organ damage in ANCA-associated vasculitis: A systematic review. RMD Open 10: e003579, 2024 10.1136/rmdopen-2023-003579 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Benichou N, Charles P, Terrier B, Jones RB, Hiemstra T, Mouthon L, et al.; French Vasculitis Study Group (FVSG) and European Vasculitis Society (EUVAS) investigators: Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis. Kidney Int 103: 1144–1155, 2023 10.1016/j.kint.2023.02.029 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Prskalo L, Skopnik CM, Goerlich N, Freund P, Wagner L, Grothgar E, et al.: Urinary CD4+ T cells predict renal relapse in ANCA-associated vasculitis. J Am Soc Nephrol 35: 483–494, 2024 10.1681/ASN.0000000000000311 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Sanchez Alamo B, Moi L, Bajema I, Faurschou M, Flossmann O, Hauser T, et al.; EUVAS: Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. Nephrol Dial Transplant 38: 1655–1665, 2023 10.1093/ndt/gfac320 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Sattui SE, Jiang B, Fu X, Cook C, Srivatsan S, Williams ZK, et al.: The effects of age and frailty on the risks of end-stage renal disease, death, and severe infection in older adults with antineutrophil cytoplasmic antibody-associated vasculitis: A retrospective cohort study. Lancet Rheumatol 6: e771–e779, 2024 10.1016/S2665-9913(24)00193-0 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Ponticelli C, Calatroni M, Moroni G: Anti-glomerular basement membrane vasculitis. Autoimmun Rev 22: 103212, 2023 10.1016/j.autrev.2022.103212 PubMed

  • 36.

    Nelveg-Kristensen KE, Madsen B, McClure M, Bruun N, Lyngso C, Dieperink H, et al.; Danish Vasculitis Association (DANVAS): Age- and time-dependent increases in incident anti-glomerular basement membrane disease: A nationwide cohort study. Clin Kidney J 17: sfad261, 2024 10.1093/ckj/sfad261 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Zhu M, Wang J, Le W, Xu F, Jin Y, Jiao C, et al.: Relationship between anti-GBM antibodies and kidney outcomes in patients with anti-GBM disease. J Nephrol 36: 789–797, 2023 10.1007/s40620-022-01508-5 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Segelmark M, Hellmark T, Wieslander J: The prognostic significance in Goodpasture’s disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. Nephron Clin Pract 94: c59–68, 2003 10.1159/000072022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Floyd L, Bate S, Hadi Kafagi A, Brown N, Scott J, Srikantharajah M, et al.: Risk stratification to predict renal survival in anti-glomerular basement membrane disease. J Am Soc Nephrol 34: 505–514, 2023 10.1681/ASN.2022050581 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Ge Y, Zhu J, Yang G, Liu K, Yu X, Sun B, et al.: Clinical characteristics and outcome of double-seropositive patients with anti-glomerular basement membrane antibodies and anti-neutrophil cytoplasmic antibodies. Int Immunopharmacol 138: 112607, 2024 10.1016/j.intimp.2024.112607 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Kuang H, Jiang N, Jia XY, Cui Z, Zhao MH: Epidemiology, clinical features, risk factors, and outcomes in anti-glomerular basement membrane disease: A systematic review and meta-analysis. Autoimmun Rev 23: 103531, 2024 10.1016/j.autrev.2024.103531 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al.: KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100: S1–S276, 2021 10.1016/j.kint.2021.05.021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Sallee M, Resseguier N, Crepin T, Bertin D, Bertrand D, Bobot M, et al.: Immunoadsorption and plasma exchange are comparable in anti-neutrophil cytoplasmic antibodies or anti-glomerular basement membrane removal kinetics. Kidney Int Rep 9: 2767–2773, 2024 10.1016/j.ekir.2024.06.031 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Uhlin F, Szpirt W, Kronbichler A, Bruchfeld A, Soveri I, Rostaing L, et al.: Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease: An open-label phase 2a study. J Am Soc Nephrol 33: 829–838, 2022 10.1681/ASN.2021111460 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Bharati J, Yang Y, Sharma P, Jhaveri KD: Atypical anti-glomerular basement membrane disease. Kidney Int Rep 8: 1151–1161, 2023 10.1016/j.ekir.2023.03.010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Shen CR, Jia XY, Cui Z, Yu XJ, Zhao MH: Clinical and immunological characteristics of patients with combined anti-glomerular basement membrane disease and IgA nephropathy. Clin Kidney J 16: 1480–1488, 2023 10.1093/ckj/sfad068 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Yang XF, Kuang H, Shen CR, Cui Z, Yu XJ, Ma YY, et al.: The prevalence and characteristics of circulating IgA anti-glomerular basement membrane autoantibodies in anti-glomerular basement membrane disease. Kidney Int Rep 8: 2395–2402, 2023 10.1016/j.ekir.2023.08.029 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Bu L, Said SM, Herrera Hernandez L, Taheri Z, Spry L, Rosenthal BS, et al.: The characteristics of concurrent anti-glomerular basement membrane nephritis and membranous nephropathy. Kidney Int Rep 8: 2164–2167, 2023 10.1016/j.ekir.2023.07.031 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Yu SM, Deoliveira M, Chung M, Lafayette R: Membranoproliferative glomerulonephritis pattern of injury. Adv Kidney Dis Health 31: 216–222, 2024 10.1053/j.akdh.2024.03.005 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Vivarelli M, Barratt J, Beck LH Jr, Fakhouri F, Gale DP, Goicoechea de JE, et al.; for Conference Participants: The role of complement in kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 106: 369–391, 2024 10.1016/j.kint.2024.05.015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Fakhouri F, Le QM, Fremeaux-Bacchi V: Practical management of C3 glomerulopathy and Ig-mediated MPGN: Facts and uncertainties. Kidney Int 98: 1135–1148, 2020 10.1016/j.kint.2020.05.053 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Roquigny J, Meuleman MS, El SC, Martins PV, Meri S, Duval A, et al.: Acquired and genetic drivers of C3 and C5 convertase dysregulation in C3 glomerulopathy and immunoglobulin-associated MPGN [published online ahead of print Nov 13, 2024]. Nephrol DialTransplant doi:10.1093/ndt/gfae243 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Meuleman MS, Vieira-Martins P, El SC, Audard V, Baudouin V, Bertrand D, et al.: Rare variants in complement gene in C3 glomerulopathy and immunoglobulin-mediated membranoproliferative GN. Clin J Am Soc Nephrol 18: 1435–1445, 2023 10.2215/CJN.0000000000000252 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Ravindran A, Fervenza FC, Smith RJH, Sethi S: C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int 94: 178–186, 2018 10.1016/j.kint.2018.01.037 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Chauvet S, Fremeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, et al.: Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood 129: 1437–1447, 2017 10.1182/blood-2016-08-737163 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Hauer JJ, Zhang Y, Goodfellow R, Taylor A, Meyer NC, Roberts S, et al.: Defining nephritic factors as diverse drivers of systemic complement dysregulation in C3 glomerulopathy. Kidney Int Rep 9: 464–477, 2024 10.1016/j.ekir.2023.11.025 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Wada Y, Kamata M, Miyasaka R, Abe T, Kawamura S, Takeuchi K, et al.: Clinico-pathogenic similarities and differences between infection-related glomerulonephritis and C3 glomerulopathy. Int J MolSci 24: 8432, 2023 10.3390/ijms24098432 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al.: Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100: 753–779, 2021 10.1016/j.kint.2021.05.015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Ahn W: Primary Nephritic Syndromes (IgA Nephropathy and Complement- and Ig-Mediated Glomerular Disease with MPGN Histology). NephSAP21: 352–363, 2022 10.1681/nsap.00462022

    • PubMed
    • Export Citation
  • 60.

    Wooden B, Nester CM, Bomback AS: Update on C3 glomerulopathy. Adv Kidney Dis Health 31: 223–233, 2024 10.1053/j.akdh.2024.05.002 PubMed

  • 61.

    Noris M, Remuzzi G: C3G and Ig-MPGN-treatment standard. Nephrol Dial Transplant 39: 202–214, 2024 10.1093/ndt/gfad182 PubMed

  • 62.

    Caravaca-Fontan F, Diaz-Encarnacion MM, Lucientes L, Cavero T, Cabello V, Ariceta G, et al.; on behalf of the Spanish Group for the Study of Glomerular Diseases GLOSEN: Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease. CJASN 15: 1287–1298, 2020 10.2215/CJN.15241219 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Caravaca-Fontan F, Cavero T, Diaz-Encarnacion M, Cabello V, Ariceta G, Quintana LF, et al.; Spanish Group for the Study of Glomerular Diseases (GLOSEN): Clinical profiles and patterns of kidney disease progression in C3 glomerulopathy. Kidney360 4: 659–672, 2023 10.34067/KID.0000000000000115 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Khandelwal P, Bhardwaj S, Singh G, Sinha A, Hari P, Bagga A: Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. Pediatr Nephrol 36: 591–600, 2021 10.1007/s00467-020-04736-8 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Lomax-Browne HJ, Medjeral-Thomas NR, Barbour SJ, Gisby J, Han H, Bomback AS, et al.: Association of histologic parameters with outcome in C3 glomerulopathy and idiopathic immunoglobulin-associated membranoproliferative glomerulonephritis. Clin J Am Soc Nephrol 17: 994–1007, 2022 10.2215/CJN.16801221 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Bomback AS, Herlitz LC, Kedia PP, Petersen J, Yue H, Lafayette RA: Safety and efficacy of avacopan in patients with C3 glomerulopathy: Randomized, double-blind clinical trial [published online ahead of print Oct 11, 2024]. J Am Soc Nephrol doi:10.1681/ASN.0000000526 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Bomback AS, Santoriello D, et al.: C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 93: 977–985, 2018 10.1016/j.kint.2017.10.022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Caravaca-Fontán F, Trujillo H, Alonso M, Díaz-Encarnación M, Cabello V, Ariceta G, et al.; C3G Study Group of the Spanish Group for the Study of Glomerular Diseases (GLOSEN): Validation of a histologic scoring index for C3 glomerulopathy. Am J Kidney Dis 77: 684–695.e1, 2021 10.1053/j.ajkd.2020.11.011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Wong E, Nester C, Cavero T, Karras A, Le QM, Lightstone L, et al.: Efficacy and safety of iptacopan in patients with C3 glomerulopathy. Kidney Int Rep 8: 2754–2764, 2023 10.1016/j.ekir.2023.09.017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Smith RJ, Kavanagh D, Vivarelli M, al el.: Efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-month results from the phase 3 APPEAR-C3G study. J Am Soc Nephrol 35: 10.1681/ASN.2024f5gka890, 2024 10.1681/ASN.2024f5gka890

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Dixon BP, Greenbaum LA, Huang L, Rajan S, Ke C, Zhang Y, et al.: Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases. Kidney Int Rep 8: 2284–2293, 2023 10.1016/j.ekir.2023.08.033 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Nester CM, Bomback AS, Ariceta Iraola MG, al el.: VALIANT: A randomized, multicenter, double-blind, placebo (PBO)-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). J Am Soc Nephrol 35: 10.1681/ASN.2024qdwvz5bg, 2024 10.1681/ASN.2024qdwvz5bg PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Caravaca-Fontan F, Lucientes L, Serra N, Cavero T, Rodado R, Ramos N, et al.: C3 glomerulopathy associated with monoclonal gammopathy: Impact of chronic histologic lesions and beneficial effects of clone-targeted therapies. Nephrol Dial Transplant 37: 2128–2137, 2022 10.1093/ndt/gfab302 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Verbinnen M, Sprangers B, Abrahams AC, Koshy P, Van Kruijsdijk RCM, Philipse E, et al.: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits in the native or posttransplant kidney. Nephrol Dial Transplant 39: 888–892, 2024 10.1093/ndt/gfae005 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Zand L, Rajkumar SV, Leung N, Sethi S, El Ters M, Fervenza FC: Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits. J Am Soc Nephrol 32: 1163–1173, 2021 10.1681/ASN.2020101541 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Coltoff A, Bomback A, Shirazian S, Lentzsch S, Bhutani D: Treatment of monoclonal gammopathy-associated C3 glomerulopathy with daratumumab-based therapy. Clin Lymphoma Myeloma Leuk 21: e674–e7, 2021 10.1016/j.clml.2021.04.011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Svabova E, Zieg J, Sukova M, Flachsova E, Kment M, Tesar V: Proliferative glomerulonephritis with monoclonal IgG deposits in an adolescent successfully treated with daratumumab. Pediatr Nephrol 39: 3455–3457, 2024 10.1007/s00467-024-06425-2 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Giang S, Agrawal AK, Oates A: Daratumumab therapy in a pediatric case of C3 nephritic factor-positive proliferative glomerulonephritis with monoclonal IgG deposits. CEN Case Rep 13: 429–433, 2024 10.1007/s13730-024-00868-0 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Nester CM, Feldman DL, Burwick R, Cataland S, Chaturvedi S, Cook HT, et al.: An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: A report of a National Kidney Foundation Working Group. Kidney Int 106: 326–336, 2024 10.1016/j.kint.2024.05.021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Khandelwal P, Nambiar S, Saini R, Saini S, Coshic P, Sinha A, et al.: Anti-factor B antibodies in atypical hemolytic uremic syndrome. Pediatr Nephrol 39: 1909–1916, 2024 10.1007/s00467-024-06284-x PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Obata S, Hullekes F, Riella LV, Cravedi P: Recurrent complement-mediated Hemolytic uremic syndrome after kidney transplantation. Transplant Rev (Orlando) 38: 100857, 2024 10.1016/j.trre.2024.100857 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Duineveld C, Bouwmeester RN, Wijnsma KL, Bemelman FJ, van der Heijden JW, Berger SP, et al.; Dutch aHUS Working Group: Eculizumab rescue therapy in patients with recurrent atypical hemolytic uremic syndrome after kidney transplantation. Kidney Int Rep 8: 715–726, 2023 10.1016/j.ekir.2023.01.016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Schaefer F, Al-Dakkak I, Anokhina K, Cohen D, Greenbaum LA, Ariceta G: Global aHUS Registry analysis of patients switching to ravulizumab from eculizumab. Kidney Int Rep 9: 2648–2656, 2024 10.1016/j.ekir.2024.06.020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 1332 1332 1220
Full Text Views 206 206 125
PDF Downloads 282 282 178